Application of the p.Q144K mutation of the SIGLEC10 gene as a marker of resistance to conservative therapy in endometrial cancer
By detecting the p.Q144K mutation of the SIGLEC10 gene, the drug resistance problem of endometrial cancer patients in childcare treatment was solved, and a detection system for predicting drug resistance was built, which improved the treatment response rate and ensured the quality of life of patients. Prognosis.
Patent Information
- Application Number
- CN202311320557.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-10-12
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-10-12
AI Technical Summary
Patients with endometrial cancer have 20%-40% resistance when receiving childcare treatment, resulting in poor treatment effect and lack of effective drug resistance prediction and molecular mechanism understanding, which affects the patient's quality of life and prognosis.
Using the p.Q144K mutation of the SIGLEC10 gene as a drug resistance marker, a specific PCR primer and immunohistochemical staining kit was developed to verify its correlation with conservation therapy resistance and through lentiviral vectors Construction experiments verify that it promotes Siglec10 protein overexpression and interacts with estrogen receptors, leading to therapeutic resistance.
A detection system was successfully built to predict the drug resistance status of endometrial cancer patients, which improved the treatment response rate, ensured the quality of life and prognosis of patients, and provided an accurate treatment stratification plan.
Smart Images

Figure CN117385036B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of endometrial cancer fertility-maintaining treatment, and in particular to application of the p.Q144K mutation of the SIGLEC10 gene as a drug resistance marker for endometrial cancer conservation treatment. Background Art
[0002] Endometrial cancer (EC) is the sixth most common cancer in women worldwide. Epidemiological statistics show that in 2020, there will be approximately 417,367 new cases and 97,370 deaths worldwide. With the growth of economic levels and changes in lifestyles, the incidence of endometrial cancer is showing a trend of younger age, and the incidence of patients under 40 years old has doubled. The increase in young patients has brought severe challenges to individuals, society and the economy. These patients are of childbearing age and have a strong desire for fertility. Currently, the most commonly used treatment option is oral high-efficiency progesterone therapy, which has demonstrated its therapeutic effect in many clinical studies. However, 20%-40% of patients still show resistance to progesterone therapy. However, the clinical and molecular characteristics and resistance mechanisms of conservation-resistant patients are still unknown. This seriously threatens the quality of life and life health of patients and limits the application of conservation therapy. Therefore, further exploration of the molecular mechanism and reversal mechanism of conservation therapy has important scientific significance and clinical application prospects.
[0003] Protein genome is an important research direction in the field of oncology. Protein genome refers to genomic information related to proteins, including protein expression levels, modification states, and interactions. By studying the protein genome in tumors, potential tumor markers can be found, which can be used for early diagnosis, prognosis evaluation, and treatment monitoring of tumors. In the study of tumor markers, the expression level of protein is an important indicator. By comparing the expression differences of proteins in tumor tissues and normal tissues, protein markers related to tumor occurrence and development can be found. These markers can be used as early screening tools to help doctors find potential tumor lesions earlier. At the same time, the expression level of proteins can also be used to assess the prognosis of tumors, judge the patient's survival period and risk of disease progression, and thus guide the choice of treatment options. However, the current protein genome research on endometrial cancer is limited to postmenopausal women in Europe and the United States, and the protein genome map of young Chinese endometrial cancer patients receiving conservation treatment is still blank. In view of this, the present invention provides the use of the p.Q144K mutation of the SIGLEC10 gene as a marker of resistance to conservation treatment of endometrial cancer. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide the application of the p.Q144K mutation of the SIGLEC10 gene as a marker of drug resistance in endometrial cancer conservation therapy. The purpose is to construct a detection system for predicting the drug resistance state of endometrial cancer patients before treatment, improve the treatment response rate of patients, and ensure the quality of life and prognosis of patients.
[0005] The technical solution of the present invention to solve the above technical problems is as follows: use of a reagent for detecting whether the protein encoded by the SIGLEC10 gene has a p.Q144K mutation in the preparation of a drug-resistant product for conservation treatment of endometrial cancer, wherein the SIGLEC10 gene has a missense mutation from cytosine (C) to adenine (A) at base 430, causing the 144th amino acid of the encoded Sigelc10 protein to mutate from glutamine to lysine.
[0006] The present invention has carried out the following three aspects of research:
[0007] (1)SIGLEC10 Q144K Screening: The marker of the present invention (p.Q144K mutation of SIGLEC10 gene, denoted as SIGLEC10 Q144K ) was obtained by differential analysis based on the results of whole exome sequencing and proteome sequencing of patients receiving conservation treatment;
[0008] (2)SIGLEC10 Q144K Verification: The present invention designs specific nested polymerase chain amplification reaction (PCR) primers and Sanger sequencing system for the p.Q144K mutation of the SIGLEC10Q gene. The results prove the existence of the p.Q144K mutation of the SIGLEC10 gene and its close correlation with resistance to conservation therapy. The present invention develops an immunohistochemical staining (IHC) kit for the Sigelc10 protein encoded by the SIGLEC10 gene, which verifies the SIGLEC10 Q144K Hotspot mutations lead to overexpression of Siglec10 protein;
[0009] (3)SIGLEC10 Q144K Promoting drug resistance in endometrial cancer conservation therapy: The present invention also constructed a lentiviral vector related to SIGLEC10, and then treated it with progesterone drugs to observe changes in cell growth and proliferation and cell death, evaluate tumor resistance by cell survival rate, and conduct immunoprecipitation experiments. The results show that SIGLEC10 Q144K Promotes overexpression of Siglec10 protein, which interacts with estrogen receptor (ERα), thereby antagonizing progesterone and leading to resistance to conservation therapy, proving that SIGLEC10 Q144KPromotes overexpression of Siglec10 protein and resists conservative treatment of endometrial cancer.
[0010] The beneficial effects of the present invention are as follows: the present invention uses the p.Q144K mutation of the SIGLEC10 gene as a marker for resistance to conservative treatment of endometrial cancer, and uses a reagent for detecting whether the protein encoded by the SIGLEC10 gene has the p.Q144K mutation in the preparation of a product for resistance to conservative treatment of endometrial cancer. A detection system for predicting the resistance status of endometrial cancer patients to conservative treatment before treatment is successfully constructed, which solves the problem of the lack of a clinical and highly accurate treatment response prediction system for patients with resistance to conservative treatment, and successfully establishes a clinically feasible precise stratification scheme for conservative treatment, which effectively improves the treatment response rate of patients and ensures the quality of life and prognosis of patients.
[0011] Based on the above technical solution, the present invention can also be improved as follows.
[0012] Furthermore, by detecting whether the protein encoded by the SIGLEC10 gene has a p.Q144K mutation, the drug resistance of patients undergoing conservation treatment of endometrial cancer can be judged. If the protein encoded by the SIGLEC10 gene has a p.Q144K mutation, the patient will develop drug resistance in the conservation treatment of endometrial cancer; if the protein encoded by the SIGLEC10 gene has not a p.Q144K mutation, the patient will not develop drug resistance in the conservation treatment of endometrial cancer.
[0013] Furthermore, the drug for the conservation treatment of endometrial cancer is progesterone.
[0014] Furthermore, the drug for the conservation treatment of endometrial cancer is medroxyprogesterone acetate (MPA), megestrol acetate (MA) or levonorgestrel-releasing intrauterine system (LNG-IUS). Among them, MPA and MA are taken orally for the conservation treatment of endometrial cancer; LNG-IUS needs to be placed in the uterus for the conservation treatment of endometrial cancer.
[0015] Furthermore, the product comprises nested primers for detecting whether the protein encoded by the SIGLEC10 gene has a p.Q144K mutation, and the nested primers comprise a first-round forward primer, a first-round reverse primer, a second-round forward primer and a second-round reverse primer.
[0016] Furthermore, the sequence of the first round forward primer is shown as SEQ ID NO: 1, the sequence of the first round reverse primer is shown as SEQ ID NO: 2, the sequence of the second round forward primer is shown as SEQ ID NO: 3, and the sequence of the second round reverse primer is shown as SEQ ID NO: 4.
[0017] Furthermore, the product includes a detection reagent or a kit.
[0018] Furthermore, the expression level of the Sigelc10 protein was detected using an immunohistochemistry kit.
[0019] Further, the immunohistochemistry kit includes environmentally friendly dewaxing solution, ethanol, PBS, antigen repair solution, EDTA, PBST, histochemical pen, goat serum, Siglec10 antibody, secondary antibody, DAB color developing solution and hematoxylin and ammonia anti-blue solution. Specifically, environmentally friendly dewaxing solution (500ml), anhydrous ethanol (1L), 95% ethanol (1L), 90% ethanol (1L), 80% ethanol (1L), PBS (50X, 500mL), antigen repair solution (20X 30mL), histochemical pen, goat serum, Siglec10 antibody, goat anti-rabbit secondary antibody, DAB color developing solution (50X 5mL), hematoxylin (500ml), hydrochloric acid differentiation solution (500ml) and ammonia anti-blue solution (500ml).
[0020] Among them, the present invention uses an immunohistochemistry kit for Siglec10 protein to predict the patient's conservation treatment response based on the immunohistochemistry results of Siglec10. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The present invention is SIGLEC10 Q144K The screening process of conservation therapy-resistant and conservation therapy-sensitive patients is shown in the somatic mutation maps obtained based on whole exome sequencing; A is a somatic mutation waterfall diagram, B is a somatic mutation frequency bar diagram, and C is a lollipop diagram of the site distribution of SIGLEC10 gene mutations;
[0022] Figure 2 For the present invention, the preservation and treatment of sensitive patients SIGLEC10 Q144K Mutation leads to overexpression of Siglec10 protein; A is the nested PCR and Sanger sequencing results verifying SIGLEC10 Q144K The existence of B is SIGLEC10 Q144K Immunohistochemical staining images of patients with and without SIGLEC10 mutations, C is SIGLEC10 Q144K correlation between mutations and immunohistochemical scores;
[0023] Figure 3 The in vitro experiments of the present invention validated SIGLEC10 Q144K Promote the mechanism of drug resistance in endometrial cancer conservation therapy; A is Western Blot validation of SIGLEC10 Q144K Promotes overexpression of Siglec10, B, C are Bioplex database and immunoprecipitation experiments showing the interaction between Sigelc10 and estrogen receptor, D, E are clone formation experiments and CCK8 experiments proving SIGLEC10 Q144K Promotes resistance of endometrial cancer to progestins. DETAILED DESCRIPTION
[0024] The principles and features of the present invention are described below, and the examples are only used to explain the present invention and are not used to limit the scope of the present invention. If no specific technology or conditions are specified in the embodiments, the technology or conditions described in the literature in this field or the product instructions are used. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased through regular channels.
[0025] Example 1: SIGLEC10 Q144K Filter
[0026] SIGLEC10 provided by the present invention Q144K The screening process includes the following steps:
[0027] a) Sample collection:
[0028] This example complies with the ethical standards of the Declaration of Helsinki, and the ethical approval numbers are [TJ-IRB20211005] and [No. 2021-181]. Written informed consent was obtained from each patient before any specific research investigation was conducted.
[0029] The present invention screened 62 patients with endometrial cancer who received conservation treatment from January 2015 to July 2020. Histological sections of tumors / adjacent tissues were taken, and hematoxylin-eosin staining (HE) was performed to determine the pathological grade of tumor tissue and the proportion of tumor cancer.
[0030] Each tumor / adjacent sample was examined by 2 pathologists, and the sample quality was confirmed according to the following criteria: (1) endometrioid endometrial carcinoma defined by histopathology; (2) the tumor cell rate (tumor purity) after removing the tumor tissue on the section was >90% under the naked eye; (3) there were no tumor cells in the adjacent paracancerous tissue. All cases were staged according to the International Federation of Gynecology and Obstetrics (FIGO) diagnostic criteria (2018). Other inclusion criteria were: patients had not received any treatment before admission, had no other malignant tumors, had no other hormone-related diseases, and had complete clinical information.
[0031] b) DNA extraction from paraffin-embedded tissues:
[0032] FFPE DNA was extracted using the MagPure FFPE DNA LQ kit (purchased from MAGEN, catalog number D6323-02). The concentration, integrity, and degree of purification of the sample were detected using a quantum dot fluorescence instrument and agarose gel electrophoresis. The specific steps included were as follows:
[0033] 1. Use surgical scissors and forceps to remove excess paraffin from stone-embedded tissues;
[0034] 2. Cut 1-3 slices of 10 μm using a microtome and transfer them to a 1.5 ml centrifuge tube; add 800 μl of Deparaffinization Solution to the sample and vortex for 5 seconds;
[0035] 3.56℃ water bath for 5 minutes; vortex mix for 15 seconds;
[0036] 4. Add 20 μl Proteinase K and 200 μl Buffer ATL to the sample; vortex to mix for 5 seconds;
[0037] 5. Briefly centrifuge to collect droplets on the tube wall; incubate at 56°C for 60-180 minutes; incubate at 90°C for 60 minutes;
[0038] 6. Briefly centrifuge to collect droplets on the tube wall; transfer the lower layer of digestion liquid to a new centrifuge tube;
[0039] 7. Add 400 μl Buffer MLE and 30 μl MagPure Particles G to the sample; vortex to mix for 15 seconds; let stand at room temperature for 3 minutes, inverting and mixing several times;
[0040] 8. Transfer to a magnetic stand and adsorb for 2-3 minutes; discard or aspirate the solution;
[0041] 9. Add 500 μl Buffer GW1, vortex for 15 seconds to resuspend the beads; transfer to the magnetic stand for adsorption for 2 to 3 minutes; discard or aspirate the solution;
[0042] 10. Add 500 μl Buffer GW1, vortex for 15 seconds to resuspend the beads; transfer to the magnetic stand for adsorption for 2-3 minutes; discard or aspirate the solution;
[0043] 11. Add 500 μl Buffer GW2 and vortex for 15 seconds to resuspend the magnetic beads;
[0044] 12. Transfer to a magnetic stand and adsorb for 2-3 minutes; discard or aspirate the solution;
[0045] 13. Repeat steps 11-12 once;
[0046] 14. Briefly centrifuge, transfer to a magnetic rack and adsorb for 1 minute, then discard all the solution;
[0047] 15. Open the tube cover and air dry for 10 minutes;
[0048] 16. Add 30-50 μl Elution Buffer, vortex to break up the magnetic beads; incubate at 55°C with shaking for 5-10 minutes;
[0049] 17. Transfer to a magnetic rack and adsorb for 2-3 minutes, then transfer the DNA to a new centrifuge tube.
[0050] c) Library construction and whole exome sequencing:
[0051] 0.2-0.5 μg FFPE DNA was randomly fragmented using a nucleic acid sonicator. TMThe dsDNA BRAssay kit (purchased from Invitrogen, catalog number Q32850) was used to select fragments with an average size of 150-250bp. The library was constructed using the KAPA Hyper preparation kit (purchased from KAPA, catalog number KK8504). These fragments were end-repaired and then 3' adenylated. The adapters were connected to the ends of these 3' adenylated fragments. These fragments were amplified using the adapters from the previous step. The PCR products were recovered using the SureSelectXT Reagent Kit (purchased from Agilent, catalog number G9611B). A certain amount of PCR product was taken and hybridized and washed with the Agilent SureSelectXT Human All Exon V6 kit (purchased from Agilent, catalog number 5190-8863). The DNA fragments captured in the previous step were amplified again, and the PCR products were recovered using magnetic beads (purchased from BGI, catalog number LB00V60). The double-stranded PCR products were heat denatured and circularized by splint oligonucleotide sequences to form single-stranded circular DNA (ssCir DNA) as the final library, which was identified by quality control. The library was amplified into DNA nanoballs (DNBs), each of which had more than 300 base pairs. On the BGIseq-500 platform (BGI-Shenzhen, China), DNBs were loaded into the plate nanoarray and double-ended 100 bp sequences were generated by combined proatorial anchor synthesis (cPAS).
[0052] d) Somatic mutation detection:
[0053] The GATK (The Genome Analysis Toolkit) Best Practice software was followed to detect somatic single nucleotide variations (SNVs) and short insertions / deletions (InDels) in the whole exome data: The present invention used BWA-mem (v0.7.15) to map the WES reads of double-end sequencing to the human reference genome (hg19). Subsequently, the aligned BAM files were preprocessed with picard (v2.22.8), and the base quality was recalibrated with GATK BaseRecalibrator (v4.1.7.0). Then, MuTect2 of GATK was used to detect SNVs and InDels from tumors and paired normal samples. VEP (v105) and vcf2maf (v1.6.21) were then used to annotate the genes of the detected somatic variations.
[0054] In order to identify driver gene mutations in endometrial cancer, the present invention uses the MutSigCV tool to identify tumor-driving genes from the tumor genome based on mutation rate and gene specificity. The MutSigCV tool is based on the fact that genes that drive tumors mutate more frequently than random mutations, so driver mutation genes can be identified by comparing the observed mutation frequency and expected mutation frequency of the gene. Therefore, the present invention uses a statistical model based on the Poisson distribution to identify genes with mutation frequencies significantly higher than expected. Specifically, the method first uses the reference genome and mutation data in the cancer sample to calculate the mutation rate of each gene, then uses various factors (such as sample contamination and tumor heterogeneity) to adjust the expected mutation rate, and finally calculates the MutSigCV score for each gene to identify driver mutation genes.
[0055] e) Screening of mutation genes related to drug resistance:
[0056] The patients were divided into two groups based on the response to conservation therapy: conservation therapy resistant (n=30) and conservation therapy sensitive (n=32). The mutation frequencies of significantly mutated genes were calculated, and Fisher's exact test or chi-square test was performed to calculate the OR value and p-value to screen the enriched somatic gene mutations in the conservation therapy resistant group. Figure 1 AC, where A is a waterfall diagram of somatic mutations, B is a bar graph of somatic mutation frequencies, and C is a lollipop diagram of the site distribution of SIGLEC10 gene mutations.
[0057] f) Results:
[0058] The results of somatic mutation differential analysis are as follows Figure 1AC showed that SIGLEC10 gene mutations were significantly enriched in patients with conservative treatment resistance (p=0.04), indicating that SIGLEC10 gene mutations promoted resistance to conservative treatment of endometrial cancer.
[0059] Example 2: SIGLEC10 Q144K Hotspot mutation verification
[0060] The present invention is directed to SIGLEC10 Q144K Specific nested polymerase chain amplification (PCR) primers and Sanger sequencing system were designed to detect SIGLEC10 Q144K The specific nested PCR primer sequence has the following base sequence:
[0061] First round forward primer SIG-F1: 5′-GAGGTCGTTGGTTTGGTTCC-3′ (SEQ ID NO: 1);
[0062] First round reverse primer SIG-R1: 5'-GTCAGTGATGGTGCCGGAG-3' (SEQ ID NO: 2);
[0063] Second round forward primer SIG-F2: 5'-AGGGGGTGGACATTCCTCAA-3' (SEQ ID NO: 3);
[0064] Second round reverse primer SIG-R2: 5'-GAATCTCCCACCACGGTCTC-3' (SEQ ID NO: 4).
[0065] The results are as follows Figure 2 As shown; the results show that SIGLEC10 Q144K Hotspot mutations exist and are closely associated with resistance to conservation therapy.
[0066] The present invention has developed a method for SIGLEC10 Q144K The immunohistochemical staining (IHC) kit for the genetically encoded Sigelc10 protein can predict the patient's conservation treatment response based on the immunohistochemical results of Siglec10. The kit includes: environmentally friendly dewaxing solution (500ml), anhydrous ethanol (1L), 95% ethanol (1L), 90% ethanol (1L), 80% ethanol (1L), PBS (50X, 500mL), antigen repair solution (20X30mL), histochemical pen, goat serum, Siglec10 antibody, goat anti-rabbit secondary antibody, DAB color development solution (50X5mL), hematoxylin (500ml), hydrochloric acid differentiation solution (500ml) and ammonia anti-blue solution (500ml).
[0067] The results are as follows Figure 2 AC shows that MT represents the occurrence of SIGLEC10 Q144K Patients with mutations, WT represents SIGLEC10 Q144K Patients without mutations. A shows the nested PCR and Sanger sequencing results confirming SIGLEC10 Q144K The existence of B is SIGLEC10 Q144K Immunohistochemical staining images of patients with and without SIGLEC10 mutations, C is SIGLEC10 Q144K Correlation of mutations with immunohistochemical scores; validation of SIGLEC10 Q144K Hotspot mutations lead to overexpression of Siglec10 protein.
[0068] Example 3: SIGLEC10 Q144K Promoting endometrial cancer conservation therapy resistance
[0069] The present invention verifies SIGLEC10 Q144K The processes that promote resistance to conservative therapy in endometrial cancer are:
[0070] a)SIGLEC10 Q144K Construction and culture of overexpression cell lines
[0071] Human endometrial cancer cell lines Ishikawa and RL95-2 were purchased from the Cell Bank of the Chinese Academy of Sciences.
[0072] Ishikawa cells were cultured in DMEM supplemented with 10% fetal bovine serum. RL95-2 cells were cultured in DMEM / F12 supplemented with 15% fetal bovine serum. Penicillin and streptomycin were added to all media. All cell lines were verified to be free of mycoplasma contamination before use and were cultured at 37°C in an incubator containing 5% CO2.
[0073] Endometrial cancer cell lines (Ishikawa and RL95-2) wt / SIGLEC10 were transfected with recombinant lentivirus SIGLEC10 (purchased from GeneCare) Q144K Overexpression plasmid (purchased from GeneCare) was used for 24 hours. pΔ8.91-pVSVG-Ubi-MCS-3FLAG-CBh-gcGFP-IRES-Puro (purchased from GeneCare) was used as the cloning vector. The titer of lentivirus was maintained at 2×10 7 IU, as a vector for transfection of SIGLEC10 wt / SIGLEC10 Q144K The overexpression plasmid was introduced into EC cell lines (Ishikawa MOI = 20; RL95-2 MOI = 60), and the density of Ishikawa cell suspension was about 4 × 10 5 / mL, the cell suspension density of RL95-2 was 2×10 6 Empty plasmid was also transfected as a negative control.
[0074] b)SIGLEC10 Q144K Detection of cell proliferation of overexpressing cell lines under progesterone stimulation
[0075] Cell viability was analyzed using Cell Counting Kit-8 (CCK8).
[0076] 1. Cells in logarithmic growth phase were cultured at 2.5×10 3 / well for inoculation and culture, and place in an incubator for overnight.
[0077] 2. Use 1.6983 mL of DMSO to dissolve 5 mg of progesterone (PRG, purchased from Selleck, product number S705) into a 10 mM storage solution, divide it into 200 uL / EP tubes, and freeze the drug solution at -80°C.
[0078] 3. After the 96-well cell culture plate adhered overnight, the 96-well plate was diluted with drugs according to the specified drug concentration (100uL culture medium / well). Each experimental group and blank control group were set up with 5 wells as replicates. The DMSO concentration of the blank control group was 3uL / mL culture medium.
[0079] 4. Based on the drug action time in the references, we discarded the culture medium in the 96-well plate at 72 hours after drug addition, diluted the CCK-8 reagent with culture medium at a ratio of 9:1 (culture medium: CCK-8 reagent stock solution), and added it to the 96-well cell culture plate.
[0080] 5. Wrap the 96-well cell culture plate with tin foil to avoid light, put it in the cell culture incubator, and let it stand for 3 to 4 hours to allow the reagents to fully react. Place the 96-well cell culture plate in an ELISA reader to detect absorbance, and set the absorption wavelength to 450nm.
[0081] c) Co-immunoprecipitation experiments
[0082] 1. Protein lysis: 50mM Tris-HCl, 150mM NaCl, 0.1% NP-40, 1X protease inhibitor complex, and adjust the pH to 7.5. Mix thoroughly and place on ice. Add 3ml of the prepared protein lysis buffer to the culture dish and continue to pipette for 30 to 50 minutes, and ensure that the whole operation is on ice. Scrape the cells, collect them, put them into a centrifuge tube and mark them.
[0083] 2. Use anti-flag magnetic beads to co-precipitate the target protein (purchased from MCE, item number HY-K0207), rinse the magnetic beads with TBST buffer (purchased from Sevier Bio, item number G2150-1L), use a magnet to adsorb the magnetic beads and absorb the waste liquid, repeat three times. Then rinse once with 0.1% NP-40 lysis buffer, and adsorb the waste liquid with a magnet. Keep 500μl of protein lysis mixture as a blank control. Put it in a minus 80 degree refrigerator overnight. Add 10μl anti-flag magnetic beads to each 500μl lysed protein lysis mixture and incubate overnight at 4°C on a rotating mixer. Take out the protein lysis mixture with magnetic beads, wash it 3 times with TBS buffer, and use a spectrophotometer to detect the spectrophotometer value of the eluate. When the spectrophotometer value is less than 0.01, it is considered that all DNA has been eluted.
[0084] 3. Add the magnetic bead-bound protein to 5X Loading Buffer and extract at 95°C for 10 minutes. Use a magnet to adsorb the magnetic beads and extract the supernatant. Then perform SDS-PAGE electrophoresis.
[0085] The results are as follows Figure 3 AE shows, where A is Western Blot verification of SIGLEC10 Q144K Promotes overexpression of Siglec10, B, C are Bioplex database and immunoprecipitation experiments showing the interaction between Sigelc10 and estrogen receptor, D, E are clone formation experiments and CCK8 experiments proving SIGLEC10 Q144K Promotes progestin resistance in endometrial cancer; results suggest that SIGLEC10 Q144K It promotes the overexpression of Siglec10 protein, which interacts with estrogen receptors, thereby antagonizing progesterone and leading to resistance to conservation therapy. Q144K Overexpression of siglec10 and siglec11 proteins promotes resistance to conservative therapy in endometrial cancer.
[0086] In summary, the present invention uses the p.Q144K mutation of the SIGLEC10 gene as a marker for resistance to conservative treatment of endometrial cancer, and uses a reagent for detecting whether the protein encoded by the SIGLEC10 gene has the p.Q144K mutation in the preparation of a product for resistance to conservative treatment of endometrial cancer. A detection system for predicting the resistance status of endometrial cancer patients to conservative treatment before treatment is successfully constructed, which solves the problem of the lack of a clinical and highly accurate treatment response prediction system for patients with resistance to conservative treatment, and successfully establishes a clinically feasible precise stratification scheme for conservative treatment, which effectively improves the treatment response rate of patients and ensures their quality of life and prognosis.
[0087] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0088] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. Use of a reagent for detecting whether the SIGLEC10 gene has c.430C>A:p.Q144K mutation in the preparation of a product for detecting progestin resistance in the conservation treatment of endometrial cancer, characterized in that: The SIGLEC10 gene has a missense mutation from cytosine to adenine at base 430, causing the 144th amino acid of the encoded Sigelc10 protein to mutate from glutamine to lysine.
2. The application according to claim 1, characterized in that: By detecting whether the protein encoded by the SIGLEC10 gene has a p.Q144K mutation, the drug resistance of patients receiving conservative treatment of endometrial cancer can be judged; the reagent for detecting whether the protein encoded by the SIGLEC10 gene has a p.Q144K mutation is a nested primer, and the nested primer includes a first-round forward primer, a first-round reverse primer, a second-round forward primer and a second-round reverse primer; the sequence of the first-round forward primer is shown in SEQ ID NO: 1, the sequence of the first-round reverse primer is shown in SEQ ID NO: 2, the sequence of the second-round forward primer is shown in SEQ ID NO: 3, and the sequence of the second-round reverse primer is shown in SEQ ID NO:
4.
3. The application according to claim 2, characterized in that: If the protein encoded by the SIGLEC10 gene undergoes a p.Q144K mutation, it will cause resistance to conservative treatment of endometrial cancer.
